Humacyte, Inc.
Nasdaq-listed company. Follow earnings, filings, products, capital and the competitive forces moving the company.
What’s moving Humacyte, Inc. now
Current reporting with the operating signal separated from the noise.
Humacyte, Inc. (HUMA) beats stock market upswing: What investors need to know
Investors are testing whether Humacyte, Inc.’s operating performance supports its strategy and valuation.
Watch next: the filing, cash flow, guidance and capital-expenditure plan.Humacyte, Inc. (HUMA) suffers a larger drop than the general market: Key insights
The story matters when it changes Humacyte, Inc.’s customers, execution, competitive position or capital requirements.
Watch next: confirmation in a company filing, official release or regulator record.Humacyte, Inc. Announces Pricing of $20 Million Registered Direct Offering of Common Stock
Investors are testing whether Humacyte, Inc.’s operating performance supports its strategy and valuation.
Watch next: the filing, cash flow, guidance and capital-expenditure plan.Is Humacyte, Inc. (HUMA) Outperforming Other Medical Stocks This Year?
Investors are testing whether Humacyte, Inc.’s operating performance supports its strategy and valuation.
Watch next: the filing, cash flow, guidance and capital-expenditure plan.Humacyte, Inc. (HUMA) Q4 2024 Earnings Conference Call Transcript
Investors are testing whether Humacyte, Inc.’s operating performance supports its strategy and valuation.
Watch next: the filing, cash flow, guidance and capital-expenditure plan.Deadline Soon: Humacyte, Inc. (HUMA) Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit
The story matters when it changes Humacyte, Inc.’s customers, execution, competitive position or capital requirements.
Watch next: confirmation in a company filing, official release or regulator record.Humacyte, Inc. Announces Pricing of $40.2 Million Public Offering of Common Stock
Investors are testing whether Humacyte, Inc.’s operating performance supports its strategy and valuation.
Watch next: the filing, cash flow, guidance and capital-expenditure plan.Latest HUMA filings.
Investor-relevant reports are shown first, followed by the company’s other recent official submissions.
Humacyte, Inc., quarter by quarter.
Results, guidance and earnings coverage are grouped only when the source headline identifies the reporting period.
First quarter
No verified period-specific item in the current feed.
SEARCH Q1 COVERAGE →Second quarter
No verified period-specific item in the current feed.
SEARCH Q2 COVERAGE →Third quarter
No verified period-specific item in the current feed.
SEARCH Q3 COVERAGE →